The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 08, 2021

Filed:

Jun. 29, 2017
Applicant:

The Regents of the University of California, Oakland, CA (US);

Inventors:

David S. Eisenberg, Los Angeles, CA (US);

Lorena Saelices Gomez, Los Angeles, CA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 7/08 (2006.01); C07K 7/06 (2006.01); G01N 33/68 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 7/08 (2013.01); C07K 7/06 (2013.01); G01N 33/6896 (2013.01); A61K 38/00 (2013.01); G01N 2800/28 (2013.01); G01N 2800/7047 (2013.01);
Abstract

The invention disclosed herein relates to peptide inhibitors for transthyretin (TTR) aggregation and methods of inhibiting TTR aggregation, cytotoxicity, and/or TTR amyloidosis. Illustrative embodiments of the invention include a composition of matter comprising at least one peptide designed to inhibit the aggregation of TTR, with this peptide typically being coupled to a heterologous amino acid tag. A pharmaceutically acceptable carrier selected to be compatible with the inhibitory peptide may also be included. A method for blocking or inhibiting the aggregation of transthyretin TTR is also provided. The method comprises combining TTR with an effective amount of an inhibitory peptide or pharmaceutical composition, so that TTR aggregation and/or cytotoxicity is blocked or inhibited.


Find Patent Forward Citations

Loading…